This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
Fabrication of AS1411 aptamer functionalized Gd₂O₃-based molecular magnetic resonance imaging (mMRI) nanoprobe for renal carcinoma cell imaging

Yue Dai ¹², Aiping Zhang ², Jia You ², Jingjing Li ¹² *, Huiting Xu ¹² *, Kai Xu ² *

Magnetic resonance imaging (MRI) as a noninvasive diagnostic technology with high spatial resolution has been widely used in clinics. However, the relative low sensitivity is the main shortcoming of this technology. To address this issue, we would like to develop a molecular MRI nanoprobe for the sensitive and specific MRI of renal carcinoma cells with BSA-Gd₂O₃ nanoparticles as MRI contrast agents, mesoporous silica nanoparticles (mSiO₂ NPs) as nanocarriers and AS1411 aptamer as targeting molecule. To achieve this aim, BSA-Gd₂O₃ NPs were assembled onto mSiO₂ NPs with the help of anionic polyelectrolyte, sodium polystyrene sulfonate (PSS), and cationic polyelectrolyte, poly dimethyl diallyl ammonium chloride (PDDA) layer by layer. Such successful assembly was confirmed by transmission electron microscopic (TEM), FT-IR spectroscopy, Zeta-potential analysis, hydrodynamic diameter determination and gel electrophoresis. After assembly, mSiO₂/PSS/PDDA/BSA-Gd₂O₃ nanoprobe presented a larger longitudinal relaxivity (r₁) (26.1 s⁻¹ mM⁻¹ Gd) than BSA-Gd₂O₃ NPs (11.8 s⁻¹ mM⁻¹ Gd) and commerically used Gd-DTPA (3.87 s⁻¹ mM⁻¹ Gd). Additionally, with AS1411 aptamer as targeting molecule, our fabricated mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 nanoprobes could recognize clear cell renal carcinoma cells (ccRCC) specifically by MRI in vitro.

Introduction

Magnetic resonance imaging (MRI), which provides inherent soft-tissue contrast, high spatial resolution and lack of ionizing radiation is thought to be one of the best strategies used in clinical diagnosis. However, the relatively low sensitivity is the major limitation of MRI technology. In order to improve the visibility of internal body structures, various MRI contrast agents (CAs) have been introduced by shorting the relaxation parameters of water.¹ As the representation of positive MRI CAs, chelated gadolinium compounds such as Gd-DTPA and Gd-DOTA are widely used in clinic to improve the contrast between normal and diseased tissues. However, it should be mentioned that the limited contrast enhancement ability, short blood circulation time and non-specificity still hampered their further applications. Particularly, with the demand of the development of molecular magnetic resonance imaging (mMRI), MRI contrast agents with better proton relaxivity and easy functionalization ability are needed urgently.² In recent years, with the development of nanotechnology, nanoparticle-based positive MRI CAs have been paid more and more attentions due to their easy design and functionalization. Gd₂O₃ nanoparticles (Gd₂O₃ NPs) as positive MRI CA have emerged to present larger T₁ relaxivity, good biocompatibility and easy conjugation with other biomolecules or imaging agents for mMRI and multimodal molecular imaging.³⁻⁵ Thus, in this study, we would like to introduce BSA-Gd₂O₃ NPs as MRI CA to fabricate AS1411 aptamer functionalized...
mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} mMRI nanoprobe to achieve better MRI contrast enhancement and specific tumor cell targeting. Mesoporous silica nanoparticles (mSiO\textsubscript{2} NPs) as nanocarriers have attracted great interest since they exhibit low cytotoxicity and excellent chemical stability and their surface can be easily modified.\textsuperscript{6,7} In terms of biocompatibility, silica is accepted as “Generally Recognized As Safe” (GRAS) by the United States Food and Drug Administration (FDA).\textsuperscript{8} Furthermore, dye-doped silica nanoparticles, called Cornell dots (C dots), have received approval from the FDA for the first Investigational NewDrug (IND) application for targeted molecular imaging of cancer.\textsuperscript{7} Decuzzi’s group has successfully confined gadolinium in the pores of mSiO\textsubscript{2} NPs to improve the relaxivity.\textsuperscript{9} In this study, we choose mSiO\textsubscript{2} NPs as the nanocarrier to load more BSA-Gd\textsubscript{3}O\textsubscript{2} NPs through layer by layer approach with the help of poly(diallyldimethylammonium chloride) (PDDA) and poly(4-styrenesulfonic acid) (PSS).

AS1411 aptamer was employed as targeting molecules due to its selective binding to nucleolin\textsuperscript{11-12} and internalized into a variety of cancer cell lines including renal, breast, and other adenocarcinoma cell lines.\textsuperscript{13-15} To confirm the specific MRI ability to tumor cells, renal cell carcinoma (RCC) were chosen as model. RCC accounts for approximately 90% of all renal malignancies.\textsuperscript{16} The main subtype of RCC is clear cell RCC (ccRCC, approximately 70%).

Results and discussion

Preparation and characterization of mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2}-AS1411 nanoprobe. Gd-based chelates as MRI contrast agents have been widely used in clinic to improve the sensitivity of MRI diagnosis. However, the chelation reduced the unpaired electrons of Gd\textsuperscript{3+} greatly, resulting in a limited proton relaxivity. Gd\textsubscript{3}O\textsubscript{2} nanoparticles with high number of gadolinium atoms were emerged to address this issue.\textsuperscript{17} In this study, BSA-Gd\textsubscript{3}O\textsubscript{2} NPs were employed as MRI contrast agent, which were prepared according to a previous report.\textsuperscript{18} In order to obtain the best MRI behavior, BSA-Gd\textsubscript{3}O\textsubscript{2} NPs were further deposited onto mesoporous SiO\textsubscript{2} (mSiO\textsubscript{2}) surface through layer by layer (LBL) assembly with the help of polyelectrolytes, PDDA and PSS. Driven by the electrostatic force, a uniform monolayer of negatively charged PSS and positively charged PDDA as well as negatively charged BSA-Gd\textsubscript{3}O\textsubscript{2} NPs were alternatively adsorbed onto the positively charged NH\textsubscript{2}-mSiO\textsubscript{2} NPs (Scheme 1). This assembly process was monitored by the determination of the changes of zeta potentials and hydrodynamic diameter. As shown in Figure 1A, the potential value of mSiO\textsubscript{2} NPs was -10 mV. After the amino group functionalization, the value was 22.6 mV. With PSS and PDDA assembly, the potential values were changed to -40.9 mV and 42.8 mV, respectively. The zeta-potential of mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} nanocomplex was -1.97 mV, which might come from the negatively charged BSA. Additionally, the hydrodynamic diameter was increased accordingly after each step of assembly (Figure 1B). They were 202.8 nm for mSiO\textsubscript{2}, 238.8 nm for mSiO\textsubscript{2}/PSS, 275.6 nm for mSiO\textsubscript{2}/PSS/PDDA, 284.3 nm for mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} and 299.1 nm for mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2}-AS1411, indicating the successful assembly. For the fabrication of specific nanoprobe, the obtained mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} nanocomplex was conjugated with AS1411 aptamer through the covalent coupling between the carboxyl group of aptamer and amino group of nanocomplex. Such conjugation was confirmed by FT-IR absorption spectrum and gel electrophoresis. The emerging absorption peak at 1620 cm\textsuperscript{-1} was ascribed to acylamide vibration, which could not be observed in the mixture of mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} and AS1411 aptamer (Figure 1C). For gel electrophoresis (Figure 1D), mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} nanocomplex (Lane 4) and mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2}-AS1411 nanoprobe (Lane 3) stayed in the well because of their relatively large size. The stronger band of mSiO\textsubscript{2} NPs and mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} nanocomplex (Lane 4) was ascribed to the conjugated AS1411 aptamer. The size and morphology of mSiO\textsubscript{2} NPs and mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2} NPs were further characterized by transmission electron microscopy (TEM), shown in Figure 2. Before LBL assembly and BSA-Gd\textsubscript{3}O\textsubscript{2} NPs loading, mSiO\textsubscript{2} exhibited uniformly ordered pores (Figure 2A). After the assembly of polyelectrolytes and BSA-Gd\textsubscript{3}O\textsubscript{2} NPs, however, the porous structure became weaker (Figure 2B), indicating the successful assembly of BSA-Gd\textsubscript{3}O\textsubscript{2} NPs on the surface of mSiO\textsubscript{2} NPs. The size of mSiO\textsubscript{2} NPs was increased from 74.01 nm to 85.24 nm after assembly.

Scheme 1. Schematic illustration of the fabrication process of mSiO\textsubscript{2}/PSS/PDDA/BSA-Gd\textsubscript{3}O\textsubscript{2}-AS1411 nanoprobes.
Figure 1. Characterization of the assembly process of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$-AS1411 nanoprobes with zeta potential (A) and hydrodynamic diameter determination (B). (C) FT-IR spectra of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$-AS1411 nanoprobes (red line), mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$-AS1411 nanocomplex (black line), AS1411 aptamer (blue line) as well as the mixture of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ and AS1411 aptamer (pink line). (D) Gel electrophoresis mobility shift characterization of the formation of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$-AS1411 nanoprobes, as visualized with ethidium bromide. Lane 1: DNA Marker (low-range); Lane 2: AS1411 aptamer; Lane 3: mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$-AS1411 nanoprobes; Lane 4: mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$. The arrow indicated AS1411 aptamer.

Figure 2. TEM images of mSiO$_2$ nanoparticles (A) and mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex (B). (C) Size distribution histograms of mSiO$_2$ nanoparticles (red color) and mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ (green color). Scale bar, 100 nm.

MRI behavior of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex. As mMRI nanoprobe, the MRI behavior of our fabricated mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex was evaluated. With different amounts of BSA-Gd$_3$O$_8$ NPs, the $T_1$ relaxation times of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex varied. As shown in Figure 3, with the increase of BSA-Gd$_3$O$_8$ NP amount, the $T_1$ relaxation time of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex was decreased gradually. But when the amount of BSA-Gd$_3$O$_8$ NPs was up to 8.48 µmol, the signal intensity reached a critical level and the $T_1$ relaxation time changed slowly with the increase of BSA-Gd$_3$O$_8$ amount. Thus, 8.48 µmol was chosen for the fabrication of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex in the following experiments. It should be noted that the existence of PDDA and PSS favored more BSA-Gd$_3$O$_8$ NPs loaded on the surface of mSiO$_2$ NPs. Positively charged NH$_2$-mSiO$_2$ NPs could adsorb negatively charged BSA-Gd$_3$O$_8$ NPs directly. However, mSiO$_2$/BSA-Gd$_3$O$_8$ displayed weaker MRI signal than mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ at the same concentrations of mSiO$_2$ and BSA-Gd$_3$O$_8$ NPs (Figure S1). The loading amounts of BSA-Gd$_3$O$_8$ NPs were determined by ICP-MS with 11.6 µmol Gd/g mSiO$_2$ for mSiO$_2$/PSS/PDDA and 49.6 µmol Gd/g mSiO$_2$ for mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$. coming from the stronger positively charged mSiO$_2$/PSS/PDDA. To further evaluate the ability of our fabricated nanocomplex as mMRI nanoprobe, the relaxivity values of Gd-DTPA, BSA-Gd$_3$O$_8$ NPs, and mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex were determined and compared by measuring longitudinal proton relaxation time ($T_1$) as a function of Gd concentration. As shown in Figure 4, the $r_1$ value of BSA-Gd$_3$O$_8$ was 11.8 s$^{-1}$ mM$^{-1}$ Gd, which was 3 times that of the commercial MRI contrast agents, Gd–DTPA ($r_1$=3.87 s$^{-1}$ mM$^{-1}$ Gd). More importantly, the relaxivity of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex was further increased to 26.1 s$^{-1}$ mM$^{-1}$ Gd. Such boost relaxivity might come from the increased molecular size after assembly. Theoretically, the proton relaxivity of Gd (III) compound is determined by the equation $r_1 = CqHμ_B^2τ_c r^6$, in which C is a constant, q is the number of inner sphere water molecules, $μ_B$ is the magnetic moment, $τ_c$ is the molecular correlation time, and $r$ is the Gd...H (H$_2$O) distance.\(^{19-21}\) The molecular correlation time $τ_c$ is determined by the following parameters: rotational correlation time $τ_ρ$, the electronic correlation time $τ_e$, and the proton residence time $τ_m$, as expressed in the equation $τ_c = τ_ρ + τ_e^{-1} + τ_m^{-1}$. To obtain higher $r_1$, improvement of $τ_c$ and $τ_m$ values is commonly considered. Changing molecular size is one of the possible approach to increase $τ_c$. Gd chelates conjugated with polymers, dendrimers, or biomacromolecules presented an increased $r_1$.\(^{22,25}\) Protein-bound Gd–DTPA has relaxivities approaching 20 mM$^{-1}$ s$^{-1}$, compared to 4 mM$^{-1}$ s$^{-1}$ for Gd–DTPA alone. In our case, $r_1$ was increased gradually with the assembly of nanocomplex, from 11.8 s$^{-1}$ mM$^{-1}$ Gd of BSA-Gd$_3$O$_8$, to 16.23 s$^{-1}$ mM$^{-1}$ Gd of mSiO$_2$/BSA-Gd$_3$O$_8$ (Figure S2), and 26.1 s$^{-1}$ mM$^{-1}$ Gd of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_8$ nanocomplex, which favored them for the fabrication of mMRI nanoprobe and their biomedical applications.
Figure 3. (A) T₁-weighted MR images and T₂-map images of mSiO₂/PSS/PDDA/BSA-Gd₂O₃ nanocomplex prepared with different amount of BSA-Gd₂O₃ NPs. (B) The corresponding T₁ relaxation time.

Figure 4. r₁ relaxivity curves (A) and T₁-weighted MR images (B) of Gd-DTPA, BSA-Gd₂O₃ nanoparticles and mSiO₂/PSS/PDDA/BSA-Gd₂O₃ nanocomplex with various Gd concentrations.

In vitro cytotoxicity. The safety assessment of nanoparticles is a vital step before their clinical applications. To evaluate the cell toxicity of the nanoprobes, MTT assay were performed to look for the potentially safe concentrations for the following targeting experiments. mSiO₂/PSS/PDDA/BSA-Gd₂O₃ nanocomplex with seven different concentrations, ranging from 100 to 1000 µg mL⁻¹, were incubated with 786-0 cells and normal human umbilical vein endothelial cells for 24 h, respectively. As shown in Figure 5, mSiO₂/PSS/PDDA/BSA-Gd₂O₃ nanocomplex displayed good biocompatibility, and no significant cytotoxicity was observed on 786-0 renal carcinoma cells or normal human umbilical vein endothelial cells even under a high concentration of 1000 µg mL⁻¹, indicating their excellent biocompatibility as mMRI nanoprobe.

In vitro MR imaging. The specific cellular targeting of mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 mMRI nanoprobe was evaluated by MRI. AS1411 aptamer as the target molecules could selectively bind to nucleolin, which overexpressed in a variety of cancer cell lines, including renal, breast, and other adenocarcinoma cell lines. The 786-0 renal carcinoma cells were incubated with mSiO₂/PSS/PDDA/BSA-Gd₂O₃ nanocomplex and mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 mMRI nanoprobes, respectively. To obtain the best signal-to-noise value, 200, 500, and 1000 µg mL⁻¹ nanoprobes were compared. As shown in Figure 6B, the higher concentration of mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 nanoprobe, the stronger signal intensity from 786-0 cells was observed. Furthermore, the presence of AS1411 aptamer could facilitate more mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 nanoprobe to bind with 786-0 cells and present a brighter MRI signal at all these three concentrations. But when the concentration of nanoprobe reached 1000 µg mL⁻¹, the non-specificity adsorption obviously existed. Thus, 500 µg mL⁻¹ mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 nanoprobe was chosen for the specific in vitro MRI finally. To further confirm such AS1411 aptamer-based specific targeting, NIH-3T3 cells and EA.hy926 cells were introduced as control and treated with 500 µg mL⁻¹ mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 nanoprobe, respectively. As shown in Figure 7A and 7B, no significant MRI signal could be observed from these two control cell lines, indicating the specific MRI ability of our fabricated nanoprobe to ccRCC in vitro. Additionally, when 786-0 cells were pretreated with AS1411 aptamer before the incubation with 500 µg mL⁻¹ mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 nanoprobe, the MRI signal was weakened obviously (Figure 7C). The binding blocking with AS1411 aptamer to nucleolin inhibited the following cellular binding with mSiO₂/PSS/PDDA/BSA-Gd₂O₃-AS1411 nanoprobe, indicating the specific MRI signal came from AS1411 aptamer.
obtained from Solarbio (China) and Aladdin (USA). Gd(NO$_3$)(APTES) and (3-aminopropyl) tetraethylorthosilicate (TEOS) were synthesized and purified by Shanghai Sangon Biotechnology Co. Ltd. (Shanghai, China). All chemicals involved in this work were synthesized according to literature procedures with some modifications.

**Preparation of mesoporous silica nanoparticles.** $\text{mSiO}_2$ NPs were synthesized according to literature procedures with some modifications. Briefly, cetyl-trimethylammonium bromide (CTAB, 1.0 g) and NaOH (aqueous) (2.00 M, 3.50 mL) were dissolved in 480 mL of double distilled water and stirred at 80°C. Subsequently, triethoxysilane (5.00 mL) was added dropwise to the solution, and the mixture was allowed to stir for 2 h at 80°C. The resultant white precipitate was isolated by centrifugation and washed with ethanol for three times. In order to remove the structure-directing agent of CTAB, the production was refluxed in a solution composed of toluene inside a round-bottom flask, and an excess of APTES (0.3 M) was added. The solution was stirred at 50°C under nitrogen for 4 h. Then it was centrifuged, washed with ethanol for three times, and dried at 60°C to obtain NH$_4$-mSiO$_2$ NPs. For the easy conjugation with target molecules, amino group was further modified on the surface of NH$_4$-mSiO$_2$ NPs. 300 mg mSiO$_2$ NPs were suspended in 20 mL anhydrous toluene inside a round-bottom flask, and an excess of APTES (0.3 M) was added. The solution was stirred at 50°C under nitrogen for 4 h. Then it was centrifuged, washed with ethanol for three times, and dried at 60°C to obtain NH$_2$-mSiO$_2$ NPs.

**Preparation of BSA-Gd$_2$O$_3$ NPs.** BSA-Gd$_2$O$_3$ NPs were synthesized according to literature procedures with some modifications. Briefly, 10 mg NH$_2$-mSiO$_2$ NPs were dispersed in 2 mL BSA-Gd$_2$O$_3$ (4.24 µmol Gd) solution and sonicated for 20 min. After determination by a microplate reader (Multiskon MK3, USA) at 490 nm. The determination of gadolinium content was performed with inductively coupled plasma-mass spectrometry (ICP-MS) (Optima 5300DV, PerkinElmer, USA). MRI scanning was performed on 3.0 T human magnetic resonance scanner (GE Signa, USA).

**Cells and cell culture.** The 786-0 renal carcinoma cells, NIH-3T3 mouse fibroblast cells and EA.hy926 normal human umbilical vein endothelial cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The 786-0 renal carcinoma cells were propagated in a 10% FBS containing RPMI 1640 medium supplemented with penicillin (100 mg/mL), and streptomycin (100 mg/mL). NIH-3T3 cells and normal human umbilical vein endothelial cells were cultured in 10% FBS-containing DMEM medium (Gibco, Grand Island, NY) supplemented with penicillin (100 mg/mL), and streptomycin (100 mg/mL). All cells were grown in a humidified incubator (Thermo, USA) at 37°C under 5% CO$_2$ atmosphere.

**Preparation of mesoporous silica nanoparticles.** $\text{mSiO}_2$ NPs were synthesized according to literature procedures with some modifications. Briefly, cetyl-trimethylammonium bromide (CTAB, 1.0 g) and NaOH (aqueous) (2.00 M, 3.50 mL) were dissolved in 480 mL of double distilled water and stirred at 80°C. Subsequently, triethoxysilane (5.00 mL) was added dropwise to the solution, and the mixture was allowed to stir for 2 h at 80°C. The resultant white precipitate was isolated by centrifugation and washed with ethanol for three times. In order to remove the structure-directing agent of CTAB, the production was refluxed in a solution composed of toluene inside a round-bottom flask, and an excess of APTES (0.3 M) was added. The solution was stirred at 50°C under nitrogen for 4 h. Then it was centrifuged, washed with ethanol for three times, and dried at 60°C to obtain NH$_2$-mSiO$_2$ NPs. For the easy conjugation with target molecules, amino group was further modified on the surface of NH$_4$-mSiO$_2$ NPs. 300 mg mSiO$_2$ NPs were suspended in 20 mL anhydrous toluene inside a round-bottom flask, and an excess of APTES (0.3 M) was added. The solution was stirred at 50°C under nitrogen for 4 h. Then it was centrifuged, washed with ethanol for three times, and dried at 60°C to obtain NH$_2$-mSiO$_2$ NPs.

**Preparation of BSA-Gd$_2$O$_3$ NPs.** BSA-Gd$_2$O$_3$ NPs were synthesized according to literature procedures with some modifications. Briefly, 10 mg NH$_2$-mSiO$_2$ NPs were dispersed in 2 mL BSA-Gd$_2$O$_3$ (4.24 µmol Gd) solution and sonicated for 20 min. After determination by a microplate reader (Multiskon MK3, USA) at 490 nm. The determination of gadolinium content was performed with inductively coupled plasma-mass spectrometry (ICP-MS) (Optima 5300DV, PerkinElmer, USA). MRI scanning was performed on 3.0 T human magnetic resonance scanner (GE Signa, USA).

**Cells and cell culture.** The 786-0 renal carcinoma cells, NIH-3T3 mouse fibroblast cells and EA.hy926 normal human umbilical vein endothelial cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The 786-0 renal carcinoma cells were propagated in a 10% FBS containing RPMI 1640 medium supplemented with penicillin (100 mg/mL), and streptomycin (100 mg/mL). NIH-3T3 cells and normal human umbilical vein endothelial cells were cultured in 10% FBS-containing DMEM medium (Gibco, Grand Island, NY) supplemented with penicillin (100 mg/mL), and streptomycin (100 mg/mL). All cells were grown in a humidified incubator (Thermo, USA) at 37°C under 5% CO$_2$ atmosphere.

**Preparation of mesoporous silica nanoparticles.** $\text{mSiO}_2$ NPs were synthesized according to literature procedures with some modifications. Briefly, cetyl-trimethylammonium bromide (CTAB, 1.0 g) and NaOH (aqueous) (2.00 M, 3.50 mL) were dissolved in 480 mL of double distilled water and stirred at 80°C. Subsequently, triethoxysilane (5.00 mL) was added dropwise to the solution, and the mixture was allowed to stir for 2 h at 80°C. The resultant white precipitate was isolated by centrifugation and washed with ethanol for three times. In order to remove the structure-directing agent of CTAB, the production was refluxed in a solution composed of toluene inside a round-bottom flask, and an excess of APTES (0.3 M) was added. The solution was stirred at 50°C under nitrogen for 4 h. Then it was centrifuged, washed with ethanol for three times, and dried at 60°C to obtain NH$_2$-mSiO$_2$ NPs. For the easy conjugation with target molecules, amino group was further modified on the surface of NH$_4$-mSiO$_2$ NPs. 300 mg mSiO$_2$ NPs were suspended in 20 mL anhydrous toluene inside a round-bottom flask, and an excess of APTES (0.3 M) was added. The solution was stirred at 50°C under nitrogen for 4 h. Then it was centrifuged, washed with ethanol for three times, and dried at 60°C to obtain NH$_2$-mSiO$_2$ NPs.
centrifugation and washed with water for three times, the mSiO$_2$/BSA-Gd$_3$O$_3$ nanocomplex were dispersed in 2 mL H$_2$O for further use. For the preparation of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanocomplex, 10 mg NH$_2$-SiO$_2$ NPs were dispersed in 2 mL PSS solution (2 mg mL$^{-1}$, 0.2 M NaCl) and sonicated for 30 min, and excess PSS was removed by centrifugation and wash with water. Then, mSiO$_2$/PSS was suspended in 2 mL PDDA solution (2 mg mL$^{-1}$, 0.2 M NaCl) and sonicated for 30 min, and excess PDDA was removed by centrifugation and wash with water. Finally, mSiO$_2$/PSS/PDDA was dispersed in different amounts BSA-Gd$_3$O$_3$ solution (1.016 µmol, 2.12 µmol, 4.24 µmol, 6.36 µmol, 8.48 µmol, 10.6 µmol, 12.72 µmol, 14.84 µmol Gd) and sonicated for 30 min. After centrifugation and wash with water for three times, mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanocomplex were dispersed in 2 mL H$_2$O for MRI scanning. AS1411 aptamer was finally functionalized onto the surface of mSiO$_2$ NPs by the covalent coupling between amino group of mSiO$_2$ and carboxyl group modified at the 5’ end of AS1411 aptamer with the help of EDC and NHS. 100 µM COOH-AS1411 (50 µL) were mixed with EDC (100 µL, 10 mg mL$^{-1}$) and reacted at 37°C for 2 h. The unreacted biomolecules were removed by two centrifugation/washing cycles. Then the mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$-AS1411 nanoprobes were dispersed in 1mL pH 7.4 PBS (10 mM) for further use.

**Gel electrophoresis analysis**

12% polyacrilamide gel was employed for the characterization of AS1411 aptamer attached to mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanocomplex. Electrophoresis was carried out at 100V for 1 h at room temperature. Low Range DNA Ladder was used as the size marker. After separation, the gel was stained with ethidium bromide and imaged using the fluorescence gel imaging system. Relaxivity calculation of BSA-Gd$_3$O$_3$ NPs, Gd-DTPA, mSiO$_2$/BSA-Gd$_3$O$_3$ and mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanocomplex. MRI behavior test of BSA-Gd$_3$O$_3$ NPs was performed with 3.0 T human magnetic resonance scanner (GE Sigma, USA). Various concentrations of BSA-Gd$_3$O$_3$ NPs solution were prepared before MRI scanning, which varied from 0.0106 mM to 2.12 mM with a volume of 600 µL. The following parameters were adopted in data acquisition.$^5$  

1. $T_1$ weighted images: echo time (TE) = 16.5 ms, repetition time (TR) = 425 ms, field of view (FOV) = 14 cm x 14 cm, matrix = 384 x 256, slice thickness = 2.0 mm, spacing = 1.5 mm;  
2. $T_1$-map images: TE = 7.4 ms, TR = 200-800 ms, FOV = 14 cm x 14 cm, matrix = 384 x 256, slice thickness = 2.0 mm, spacing = 1.5 mm.  

Quantitative $T_1$ relaxation maps were reconstructed from datasets using function software at a workstation (ADW 4.2). The signal intensity of the samples was measured, and the $T_1$ values were calculated accordingly. MRI scans of Gd-DTPA and mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanoprobes with different amount were carried out in the same way. The relaxivity values of BSA-Gd$_3$O$_3$ NPs, Gd-DTPA, mSiO$_2$/BSA-Gd$_3$O$_3$ and mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanoprobes were determined by measuring longitudinal proton relaxation time ($T_1$) as a function of Gd concentration.

**MTT assay**

786-0 cells and EA.hy926 normal human umbilical vein endothelial cells were cultured on 96-well plates at a density of 10$^4$ cells each well. After 24 h incubation, the medium was substituted with 100 µL of fresh medium containing different concentrations of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanocomplex (0, 100, 200, 400, 500, 600, 800, 1000 µg mL$^{-1}$). After 4 h incubation, the medium was removed, and fresh medium (100 µL) containing MTT (20 µL, 5 mg mL$^{-1}$) was added into each well. Four hours later, the culture medium was carefully removed, and 100 µL dimethyl sulfoxide (DMSO) was added to each well to dissolve the formazan crystals for 10 min. The absorbance at 490 nm was measured by microplate reader (Multiskan MK3, USA).

**In vitro specific targeting of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$-AS1411 mMRI nanoprobe to 786-0 cells**

The 786-0 cells were seeded into 6-well plates at a density of 10$^5$ cell/well (2 mL) and cultured for 24 h in a humidified incubator at 37°C under 5% CO$_2$ atmosphere, respectively. Then, the culture media was removed and the cells were washed with PBS twice. Afterward, 500 µL different concentrations of mSiO$_2$/PSS/PDDA/Gd$_3$O$_3$-AS1411 (200, 500, 1000 µg mL$^{-1}$) and mSiO$_2$/PSS/PDDA/Gd$_3$O$_3$ (200, 500, 1000 µg mL$^{-1}$) were added into the well respectively. After 1 h incubation at 37°C, the free nanoparticles were removed and the cells were washed and lysed by trypsin. The cells that harvested by centrifugation at 1000 rpm for 10 min were mixed by 500 µL paraformaldehyde solution and kept at 4°C for MRI scanning. The untreated cells that incubated with culture medium were taken as control. For the $T_1$ relaxation time determination, the harvested cells were incubated in 300 µL of 1% agarose for axial MRI scanning as well. For control experiment, NIH-3T3 cells and EA.hy926 normal human umbilical vein endothelial cells were seeded as 786-0 cells. After incubated with 0 and 500 µg mL$^{-1}$ mSiO$_2$/PSS/PDDA/Gd$_3$O$_3$-AS1411, the cells were harvested and imaged on MRI scanner.

**Conclusions**

In summary, we fabricated a mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$-AS1411 mMRI nanoprobe for the specific MRI of renal carcinoma cells by layer by layer approach. The present of polyelectrolytes, PDDA and PSS increased the loading amount of BSA-Gd$_3$O$_3$ NPs on the surface of mSiO$_2$ and improved the longitudinal relaxivity $r_1$ of mSiO$_2$/PSS/PDDA/BSA-Gd$_3$O$_3$ nanocomplex significantly. With the help of AS1411 aptamer specific targeting to nucleolin, the fabricated nanoprobes could recognize clear cell renal carcinoma cells sensitively and specifically in vitro.

**Acknowledgements**

This work was supported by National Natural Science Foundation of China (21305120, 81470075), Natural Science Foundation of Jiangsu Province (BK20130211), and Natural Science Fund for Colleges and Universities in Jiangsu Province (13KJB150036).

**Notes and references**


